Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers

What Was Tested

This clinical trial paper looks at IGF-1 LR3 and Octreotide.

Eight healthy male volunteers, given an iv infusion of octreotide to suppress the endogenous GH secretion during the study period, participated in the study.

No volunteers were withdrawn due to side effects.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, men only.

This was a single-center, nonrandomized placebo-controlled, open-label, five-way crossover study in eight healthy volunteers.

How the Study Was Run

The researchers set it up as an open-label, placebo-controlled and crossover study.

Everyone knew when IGF-1 LR3 was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

A placebo (an inactive look-alike) gave the IGF-1 LR3 group a baseline to be compared against.

Each person switched between IGF-1 LR3 and the comparison at some point, usually with a gap in between.

The study was carried out at a contract research organization, Quotient Bioresearch.

What Was Measured

Topics PubMed links to this paper include Healthy Volunteers, Human Growth Hormone, Insulin-Like Growth Factor I, Octreotide and Recombinant Proteins.

What This Means in Plain Language

The paper is an open-label, placebo-controlled and crossover study of IGF-1 LR3 and Octreotide.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the IGF-1 LR3 compound page and the Octreotide compound page, all human trials.